stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Net income
HUTCHMED (China) Limited Sponsored ADR's net income for fiscal 2025 was $457.7M, up 1,099.2% from $38.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was $967.7M. Over the past ten years it has ranged from −$360.4M (fiscal 2022) to $457.7M (fiscal 2025) — the current reading is the highest in ten years. HUTCHMED (China) Limited Sponsored ADR ranks 5th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $457.7M | 1,099.19% |
| FY2024 | $38.2M | (62.24%) |
| FY2023 | $101.1M | — |
| FY2022 | −$360.4M | — |
| FY2021 | −$167.0M | — |
| FY2020 | −$115.5M | — |
| FY2019 | −$103.7M | — |
| FY2018 | −$71.3M | — |
| FY2017 | −$23.0M | — |
| FY2016 | $14.6M | 39.61% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $16.2M | (96.45%) |
| Dec 2025 | $457.7M | 0.48% |
| Jun 2025 | $455.6M | 1,093.49% |
| Dec 2024 | $38.2M | 45.88% |
| 11 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR | $967.7M |
| PBH Prestige Consumer Healthcare Inc. compare | $155.1M |
| ANIP ANI Pharmaceuticals, Inc. compare | $116.8M |
| XERS Xeris Biopharma Holdings, Inc. compare | −$6.5M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.0M |
| ALVO Alvotech compare | −$179.6M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$359.7M |
| TRLV Trulieve Cannabis Corp. compare | −$446.6M |
| PRGO Perrigo Company plc compare | −$1.8B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on HCM
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement